Comparison of antibody response between covishield & covaxin by @singhak_endo & team.
515 subjects, of whom 90 got covaxin
95% overall anti Spike antibody response
98% for covishield, 80% for covaxin
Lower response in older people & diabetes
🧵
1/5
medrxiv.org/content/10.110…
515 subjects, of whom 90 got covaxin
95% overall anti Spike antibody response
98% for covishield, 80% for covaxin
Lower response in older people & diabetes
🧵
1/5
medrxiv.org/content/10.110…
Cont’d
Antibody titre 115 AU/ml for Covishield and 51 for covaxin.
27 breakthrough infections occurred (4.9%) after both doses: 25 were mild, 2 were moderate, no deaths.
Risk of breakthrough infection:
5.5% with covishield
2.2% with covaxin
2/5
Antibody titre 115 AU/ml for Covishield and 51 for covaxin.
27 breakthrough infections occurred (4.9%) after both doses: 25 were mild, 2 were moderate, no deaths.
Risk of breakthrough infection:
5.5% with covishield
2.2% with covaxin
2/5
Listing some facts which will help understand the context of the study:
1. Anti Spike antibody is not the same as neutralising antibody. Its level is not known to reliably correlate with NAb, which is typically measured only in research labs. See my earlier tweet on this.
3/5
1. Anti Spike antibody is not the same as neutralising antibody. Its level is not known to reliably correlate with NAb, which is typically measured only in research labs. See my earlier tweet on this.
3/5
2. Immunity is multipronged, like the “Army, Navy and Airforce”. Antibodies form only one segment of this.
⚠️The % or level of Anti Spike Antibody measured in the study cannot be taken as “% of protection delivered” to the recipient.
4/5
⚠️The % or level of Anti Spike Antibody measured in the study cannot be taken as “% of protection delivered” to the recipient.
4/5
3. What matters in the end is:
a) the % of people who get infected inspite of vaccination
b) how sick they get
c) duration of protection
Both vaccines are seen to be providing excellent protection on the ground. The exact %, as the authors say, will only be seen in an RCT.
5/5
a) the % of people who get infected inspite of vaccination
b) how sick they get
c) duration of protection
Both vaccines are seen to be providing excellent protection on the ground. The exact %, as the authors say, will only be seen in an RCT.
5/5
Congratulations to Dr AK Singh @singhak_endo and colleagues for conducting this study and for writing it up comprehensively using professional language, covering all possible angles, discussing the limitations and correlating with published research.
Study by Dr Padmanabha Shenoy @drdpshenoy and co from Cochin shows similar trends, although their work was primarily among patients with rheumatological disease.
https://twitter.com/drdpshenoy/status/1401484215862972418
• • •
Missing some Tweet in this thread? You can try to
force a refresh
